Effect of canonical aryl hydrocarbon receptor pathway inhibitor on human endothelial cells
To study the effect of blockade of canonical aryl hydrocarbon receptor (AHR) pathway in human endothelial cells, we treated human umbilical vein endothelial cells (HUVECs) and adipose endothelial cells with a canonical AHR inhibitor, Stemreginin 1 (SR1) and performed bulk RNAseq analysis. Overall design: HUVECs and adipose endothelial cell lines were derived from human donors. Cells from each patient were treated with either 1: 10, 000 DMSO (vehicle), or 0.5uM SR1 in 1: 10, 000 DMSO. At different time points, RNA samples were collected for comparisons.